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Rosario, Rosario, Argentina; Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada; 8Division of Cardiology, St. Michael’s Hospital, University of Toronto,
Toronto, ON, Canada; 9Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; 10R & D clinical Development, Sanofi, Paris, France; 11Clinical
Sciences-Cardiovascular & Metabolism Therapeutics, Regeneron Pharmaceuticals, Tarrytown, NY, USA; 12Cardiovascular Research Institute Basel (CRIB) and Department of
Cardiology, University Hospital Basel, University of Basel, Switzerland; 13Institute of Cardiology, Kyiv, Ukraine; 14Department of Medicine, Ramathibodi Hospital, Bangkok,
Thailand; 15State University of New York, Downstate School of Public Health, Brooklyn, NY, USA; 16Green Lane Cardiovascular Services Auckland City Hospital, Auckland, New
Zealand; 17Department of Medicine III, Goethe University, Frankfurt am Main, Germany; and 18Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA
Received 30 January 2020; revised 18 April 2020; editorial decision 27 May 2020; accepted 29 May 2020; online publish-ahead-of-print 21 August 2020
See page 4124 for the editorial comment on this article (doi: 10.1093/eurheartj/ehaa550)
Aims Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately
impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
provide similar benefit across a range of renal function. We determined whether effects of the PCSK9 inhibitor alir-




ODYSSEY OUTCOMES compared alirocumab with placebo in patients with recent ACS and dyslipidaemia despite
intensive statin treatment. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 was exclusionary. In 18
918 patients, baseline eGFR was 82.8 ± 17.6 mL/min/1.73 m2, and low-density lipoprotein cholesterol (LDL-C) was
92 ± 31 mg/dL. At 36 months, alirocumab decreased LDL-C by 48.5% vs. placebo but did not affect eGFR (P = 0.65).
Overall, alirocumab reduced risk of the primary outcome (coronary heart disease death, non-fatal myocardial infarc-
tion, ischaemic stroke, or unstable angina requiring hospitalization) with fewer deaths. There was no interaction
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between continuous eGFR and treatment on the primary outcome or death (P = 0.14 and 0.59, respectively).
Alirocumab reduced primary outcomes in patients with eGFR >_90 mL/min/1.73 m2 (n = 7470; hazard ratio
0.784, 95% confidence interval 0.670–0.919; P = 0.003) and 60 to <90 (n = 9326; 0.833, 0.731–0.949;
P = 0.006), but not in those with eGFR < 60 (n = 2122; 0.974, 0.805–1.178; P = 0.784). Adverse events other
than local injection-site reactions were similar in both groups across all categories of eGFR.
...................................................................................................................................................................................................
Conclusions In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the
range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2.
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Introduction
Patients with chronic kidney disease (CKD) are at high risk for major
adverse cardiovascular events (MACE).1–3 Several factors may ac-
count for this high risk. First, CKD is associated with other estab-
lished risk factors, including age, hypertension, and diabetes. Second,
lipoprotein abnormalities frequently accompany CKD, including
increased triglycerides, decreased high-density lipoproteins, and an
excess of small, dense low-density lipoprotein particles.2 Third, CKD
is associated with elevated inflammatory biomarkers,4 abnormal
platelet function,5 and extensive vascular calcifications.6
Statins decrease the incidence of cardiovascular events in patients
with moderate-to-severe CKD,7 but not in those on dialysis.8,9
Although some guidelines suggest the use of moderate-dose statins
in patients with moderate-to-severe CKD,10 the recent US guidelines
on the management of blood cholesterol consider CKD stages 3 or 4
to be one of the ‘very high risk’ conditions that warrant the use of
high-intensity or maximum-tolerated statin treatment for secondary
prevention, and the addition of ezetimibe or an inhibitor of propro-
tein convertase subtilisin-kexin type 9 (PCSK9) if low-density lipo-
protein cholesterol (LDL-C) remains above 70 mg/dL.3 Similarly,
recent European guidelines indicate that a goal of treatment in
patients with moderate-to-severe CKD is to ‘achieve the largest pos-
sible absolute reduction in LDL-C safely’.11
The PCSK9 inhibitors alirocumab12 and evolocumab13 decrease
the incidence of cardiovascular events in patients with acute coron-
ary syndromes (ACS) and chronic atherosclerotic cardiovascular dis-
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significant safety concerns in patients with CKD.14 Likewise, evolocu-
mab therapy was associated with reduced MACE in patients with
CKD and chronic atherosclerosis treated with statins.15
Patients with CKD and ACS are at particularly high risk for recur-
rent MACE. The efficacy and safety of PCSK9 inhibition in such
patients has not previously been investigated. In this prespecified ana-
lysis of the ODYSSEY OUTCOMES trial, we examined whether the
reduction of MACE with alirocumab, added to intensive or
maximum-tolerated statin therapy after ACS, depends upon the level
of estimated glomerular filtration rate (eGFR).
Methods
Trial design
The design16 and primary efficacy and safety results12 of the ODYSSEY
OUTCOMES trial (clinicaltrials.gov: NCT01663402) have been pub-
lished. Ethics committee approval was obtained at all participating
centres. All participants provided written informed consent. The trial was
a randomized, double-blind, placebo-controlled comparison of alirocu-
mab or placebo in 18 924 patients with an ACS (myocardial infarction or
unstable angina) 1–12 months before randomization. Qualifying patients
had persistent dyslipidaemia [LDL-C >_ 70 mg/dL (1.81 mmol/L), non-
high-density lipoprotein cholesterol (non-HDL-C) >_100 mg/dL
(2.59 mmol/L), or apolipoprotein B >_ 80 mg/dL (0.0016 mmol/L)] despite
treatment with atorvastatin 40–80 mg daily, rosuvastatin 20–40 mg daily,
or the maximum-tolerated dose of one of these statins (including no sta-
tin in case of documented intolerance). An eGFR of <30 mL/min/1.73 m2
at the screening visit for the study was an exclusion criterion. At the ran-
domization visit, baseline laboratory studies were obtained, and partici-
pants were randomly assigned (1:1) to receive alirocumab 75 mg or
matching placebo subcutaneously every 2 weeks. A treat-to-target design
aimed to achieve an LDL-C level of 25–50 mg/dL among alirocumab-
treated patients. Alirocumab 75 mg was blindly up-titrated to 150 mg if
the LDL-C level was >50 mg/dL. If LDL-C was <15 mg/dL on two con-
secutive measurements on the 75 mg dose of alirocumab, placebo was
blindly substituted for the rest of the trial. Participants and physicians
were blinded to the treatment allocation. To protect the blind, all treat-
ment kit boxes had the same look and feel and were labelled with a
double-blind label. Details on randomization procedures are included in
Supplementary material online.
The primary outcome was a composite of MACE, including death due
to coronary heart disease, non-fatal myocardial infarction, ischaemic
stroke, or unstable angina requiring hospitalization. Death from any cause
was a secondary outcome. All outcomes were blindly adjudicated.
In this prespecified analysis, we investigated whether the effect of aliro-
cumab on MACE and death varied across the range of baseline renal func-
tion, gauged by eGFR calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation.17 We also analysed the incidence
of adverse effects as a function of eGFR, and looked for potential effects
of alirocumab on eGFR.
Statistical analysis
Details on the sample size calculation are included in the Supplementary
material online. The comparisons of baseline differences among eGFR
subgroups were tested using the v2 test for categorical variables and ana-
lysis of variance for continuous variables, except for triglycerides and lipo-
protein(a), which were tested using median regression due to their
skewed distributions. Efficacy analyses were performed on an intention-
to-treat basis. Incidence rates per 100 patient-years for MACE and all-
cause death were estimated by treatment groups in each decile of base-
line eGFR, and smoothed curves were fit to estimations based on each
eGFR decile subgroup using local regression. Interactions between study
treatment and baseline eGFR for MACE and death were tested using pro-
portional hazard models, using either eGFR subgroups or a continuous
value of eGFR. Differences in eGFR at Month 36 between treatment
groups were assessed using the Student’s t-test. Differences between
treatment groups in the proportion of adverse events were evaluated
using the v2 test. This test was also used to compare treatment differen-
ces in the percentages of patients whose eGFR at the end of treatment
was reduced by 30%, 40%, or 50% from baseline. Statistical significance
was set at P < 0.05 (two-sided) without multiplicity adjustment. Analyses
were performed in SAS version 9.4.
Results
A total of 18 924 patients underwent randomization at 1315 sites in
57 countries (Supplementary material online, Table S1). Of these,
9462 were assigned to alirocumab and 9462 to placebo (Figure 1).
Outside of China, patients were randomized between November
2012 and November 2015. In China, 613 patients were randomized
between May 2016 and February 2017. In this analysis, 6 of the
patients (4 in the placebo group and 2 in the alirocumab group) were
excluded because their baseline serum creatinine values were not
available, leaving 18 918 patients for the analysis (9460 in the alirocu-
mab group and 9458 in the placebo group). Median follow-up was
2.8 (interquartile range 2.3–3.4) years.
In the aggregate trial cohort, baseline eGFR was 82.8 ± 17.6 mL/
min/1.73 m2. There were 7470 (39.5%) patients with eGFR >_90 [98.6
(94.3, 103.5)] mL/min/1.73 m2, 9326 (49.3%) with eGFR 60 to <90
[77.8 (70.6, 84.2)] mL/min/1.73 m2, and 2122 (11.2%) with eGFR <60
[51.4 (44.2, 56.1)] mL/min/1.73 m2. While eGFR <30 mL/min/1.73 m2
was a screening exclusion criterion, 69 patients (0.4%) had eGFR
<30 mL/min/1.73 m2 at randomization and were included in the ana-
lysis. Supplementary material online, Table S2 shows the distribution
of the population according to eGFR range and study treatment. Of
patients receiving alirocumab, 7.8% were switched to placebo, pri-
marily due to two consecutive LDL-C values <15 mg/dL (0.39 mmol/
L) in the subgroups with eGFR <60 and 60 to <90 mL/min/1.73 m2,
and 7.6% in the subgroup with eGFR >_90 mL/min/1.73 m2.
Baseline characteristics of the population across eGFR subgroups
are shown in Supplementary material online, Table S3. Overall,
patients with lower eGFR were older; more likely to have a history of
hypertension, diabetes, myocardial infarction, coronary revasculariza-
tion, stroke, peripheral artery disease, and heart failure; and had
higher levels of triglycerides and lipoprotein(a). In addition, patients
with lower eGFR were less likely to receive intensive statin treatment
and dual antiplatelet therapy but were more likely to receive inhibi-
tors of the renin–angiotensin system and oral anticoagulants.
At baseline, mean LDL-C was 92 ± 31 mg/dL in both treatment
groups. Alirocumab decreased LDL-C by 62.2% and 48.5% vs. pla-
cebo at 4 and 36 months, respectively. The effect of alirocumab on
LDL-C was consistent across eGFR subgroups at 4 months: the LDL-
C values of patients on alirocumab were 40± 30 mg/dL in the eGFR
<60 mL/min/1.73 m2 subgroup, 38 ± 30 mg/dL in the 60 to <90 mL/
min/1.73 m2 subgroup, and 38± 28 mg/dL in the >_90 mL/min/1.73 m2
subgroup. At 36 months, these values were 52 ± 36, 56± 40, and
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Figure 1 Consort diagram. *The most common reasons for screen failures during the run-in period were related to lipid criteria (34.1% of patients)
or withdrawal of patient consent (6.1% of patients). From Schwartz et al.12 Copyright VC (2018) Massachusetts Medical Society. Reprinted with
permission.
















..60± 42 mg/dL, respectively (Figure 2 and Supplementary material on-
line, Table S4). Supplementary material online, Figures S1–S4 show the
effect of alirocumab on apolipoprotein B, triglycerides, HDL-C, and
non-HDL-C, respectively, across the three categories of eGFR.
Alirocumab decreased apolipoprotein B and non-HDL-C and
increased HDL-C homogeneously across eGFR categories. At
baseline, triglyceride levels were higher in patients with eGFR
<60 mL/min/1.73 m2 than in the other two subgroups and the de-
crease in triglycerides with alirocumab was greatest in that eGFR
category.
Overall, alirocumab reduced incident MACE [9.5% vs. 11.1%; haz-
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Figure 2 Low-density lipoprotein cholesterol values achieved over time according to treatment in each estimated glomerular filtration rate cat-






























Baseline eGFR (mL/min/1.73 m2)
Death
Take home figure Incidence of major adverse cardiovascular event and death per 100 patient-years at risk according to estimated glomerular
filtration rate as a continuous variable. There was no significant interaction between the use of alirocumab and the estimated glomerular filtration rate
for major adverse cardiovascular event (P¼ 0.14) or all-cause death (P¼ 0.59). eGFR, estimated glomerular filtration rate; MACE, major adverse car-
diovascular event.



































































associated with fewer deaths (3.5% vs. 4.1%; HR 0.85, 95% CI 0.73–
0.98). The incidences of MACE and death over the range of baseline
eGFR are presented in the alirocumab and placebo groups in the
Take home figure. The annualized incidence rates for MACE and death
increased progressively as eGFR decreased, beginning at eGFR values
<80 mL/min/1.73 m2. Patients receiving alirocumab had fewer MACE
and deaths than those on placebo across all values of eGFR. There
were no significant interactions of assigned treatment (alirocumab or
placebo) and eGFR on the incidence rates for MACE and death
(P¼ 0.14 and P¼ 0.59, respectively).
When the population was divided in subgroups according to CKD
stage, alirocumab was associated with a significant reduction in the in-
cidence of MACE in patients with eGFR >_90 mL/min/1.73 m2 and be-
tween 60 and <90 mL/min/1.73 m2 (Table 1), but not in patients with
eGFR <60 mL/min/1.73 m2. In all three subgroups, there were nu-
merically fewer deaths in patients receiving alirocumab, without stat-
istical significance in any individual category. The interaction P-value
between eGFR and alirocumab was 0.21 for MACE and 0.83 for
death.
When the population was divided into quintiles according to
eGFR, patients on alirocumab had a lower incidence of MACE in all
the quintiles (Supplementary material online, Figure S5A). Similar find-
ings were observed for the incidence of death, with the exception of
quintile 2, where it was similar in both groups (Supplementary mater-
ial online, Figure S5B).
At baseline, eGFR was 82.7± 17.7 mL/min/1.73 m2 in the alirocu-
mab group and 82.9 ± 17.6 mL/min/1.73 m2 in the placebo group.
Alirocumab had no effect on eGFR over the duration of the trial; for
example, at 36 months, these values were 83.9 ± 18.0 and
84.1± 17.6 mL/min/1.73 m2, respectively (P = 0.65) (Supplementary
material online, Figure S6). The percentages of patients having a de-
crease in eGFR from baseline of at least 30% [1.8% (n = 170) vs. 2.1%
(n = 202); P = 0.09], 40% [0.8% (n = 78) vs. 0.9% (n = 87); P = 0.48], or
50% [0.3% (n = 30) vs. 0.4% (n = 34); P = 0.62, for alirocumab and pla-
cebo, respectively] were similar in both treatment groups.
In the overall trial population and in each category of baseline
eGFR, compared with patients on placebo, patients in the alirocumab
group had a higher incidence of local injection-site reactions, without
any excess of all treatment-emergent adverse events, serious adverse
events, adverse events leading to death, rhabdomyolysis, or increases
in liver enzymes or creatine kinase (Table 2).
Discussion
This is the first analysis of the effects of a PSCK9 inhibitor on clinical
outcomes according to renal function in post-ACS patients. In this
prespecified analysis, we found that alirocumab had a consistent ef-
fect on plasma LDL-C and on the incidence of MACE across the
range of baseline renal function of patients in the study. Subgroup
analysis showed a significant decrease in the incidence of MACE
among patients with eGFR 60 to <90 or >90 mL/min/1.73 m2. The
decrease was not significant in patients with eGFR <60 mL/min/1.73
m2. There was no excess of any adverse event other than local
injection-site reactions with alirocumab compared with placebo in
any category of eGFR. Alirocumab or placebo treatment did not in-
fluence the level of eGFR at 36 months after randomization.
Patients with CKD are at high risk of developing cardiovascular
events.1–3 Statins with or without ezetimibe decrease cardiovascular
risk in patients with moderate-to-severe CKD.7,18,21 However, part
of the benefit of statins in this setting may be counterbalanced by an
increased risk of adverse events.18 Furthermore, this benefit seems
to decrease as eGFR declines, with little or no benefit in patients on
dialysis.8,9,19 Given this background, it cannot be assumed that the
balance of efficacy and safety with a lipid-lowering drug in a broad
population applies similarly to patients with CKD.
Proprotein convertase subtilisin-kexin type 9 inhibitors are power-
ful lipid-lowering drugs, decreasing LDL-C, apolipoprotein B, trigly-
cerides, and lipoprotein(a), without evidence to date of any serious
safety concerns.13,20 A subanalysis of the FOURIER (Further
Cardiovascular Outcomes Research With PCSK9 Inhibition in
Patients With Elevated Risk) trial in patients with chronic atheroscler-
otic cardiovascular disease demonstrated that evolocumab reduced
the incidence of cardiovascular events across CKD subgroups.15
Here, we present the first evidence of the effects of a PCSK9 inhibitor
according to renal function in patients 1–12 months post-ACS.
............................................................................
....................................................................................................................................................................................................................
Table 1 Effect of alirocumab on the incidence of MACE and death in different subgroups according to eGFR




<60 2122 7.9 8.1 0.2 0.97 (0.81–1.18) 0.78
60 to <90 9326 3.2 3.9 0.7 0.83 (0.73–0.95) 0.006
>_90 7470 2.7 3.5 0.8 0.78 (0.67–0.92) 0.0026
All-cause death 0.83
eGFR (mL/min/1.73 m2)
<60 2122 3.4 3.8 0.4 0.90 (0.69–1.18) 0.46
60 to <90 9326 1.2 1.4 0.2 0.82 (0.66–1.01) 0.07
>_90 7470 0.7 0.9 0.2 0.81 (0.60–1.10) 0.18
ARR, absolute risk reduction; CI, confidence interval; eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular event.





















..Overall in the ODYSSEY OUTCOMES trial, treatment with aliro-
cumab decreased the incidence of MACE and was associated with
fewer total deaths.12 Of the patients in the trial, 60% had an eGFR
<90 mL/min/1.73 m2, reflecting at least mild CKD, and 10.9%
(n = 2053) had an eGFR of 30 to <60 mL/min/1.73 m2, indicating
moderate CKD. The low number of patients in the latter category
limited power to determine an effect of alirocumab on MACE or
death. The FOURIER trial was larger than ODYSSEY OUTCOMES,
included more than twice the number of patients with eGFR
<60 mL/min/1.73 m2 (n = 4443), and had a different primary MACE
endpoint of cardiovascular death, myocardial infarction, stroke, hos-
pitalization for unstable angina, or coronary revascularization.
Notwithstanding these differences, the qualitative findings in both tri-
als are similar. In both, there was no difference in treatment effects of
PCSK9 inhibition on LDL-C, apolipoprotein B, non-HDL-C or HDL-
C across categories of eGFR, and a larger absolute decrease in trigly-
cerides in patients with eGFR <60 mL/min/1.73 m2. In both trials, the
point estimate of the treatment HR for the primary Endpoint was
....................................................................................................................................................................................................................
Table 2 Incidence of TEAEs according to baseline eGFR category
Alirocumab Placebo P value
All patients (n=9460) (n=9458)
Any TEAE, n (%) 7164 (75.7) 7278 (77.0) 0.0481
Any serious TEAE, n (%) 2201 (23.3) 2350 (24.8) 0.011
TEAE leading to death, n (%) 181 (1.9) 222 (2.3) 0.0388
TEAE leading to discontinuation, n (%) 343 (3.6) 324 (3.4) 0.456
Local injection-site reaction, n (%) 360 (3.8) 203 (2.1) <0.0001
AST >3 times ULN, n (%) 169 (1.8) 161 (1.7) 0.658
ALT >3 times ULN, n (%) 218 (2.3) 219 (2.3) 0.960
Creatine kinase >10 times ULN, n (%) 49 (0.5) 47 (0.5) 0.839
Rhabdomyolysis, n (%) 22 (0.2) 17 (0.2) 0.423
Baseline eGFR <60 mL/min/1.73 m2 (n=1077) (n=1045)
Any TEAE, n (%) 863 (80.1) 852 (81.5) 0.413
Any serious TEAE, n (%) 353 (32.8) 366 (35.0) 0.274
TEAE leading to death, n (%) 48 (4.5) 65 (6.2) 0.071
TEAE leading to discontinuation, n (%) 56 (5.2) 53 (5.1) 0.894
Local injection-site reaction, n (%) 28 (2.6) 16 (1.5) 0.084
AST >3 times ULN, n (%) 23 (2.1) 19 (1.8) 0.560
ALT >3 times ULN, n (%) 34 (3.2) 22 (2.1) 0.131
Creatine kinase >10 times ULN, n (%) 6 (0.6) 8 (0.8) 0.553
Rhabdomyolysis, n (%) 3 (0.3) 2 (0.2) 0.679
Baseline eGFR >_60 to <90 mL/min/1.73 m2 (n=4669) (n=4657)
Any TEAE, n (%) 3565 (76.4) 3591 (77.1) 0.388
Any serious TEAE, n (%) 1085 (23.2) 1179 (25.3) 0.019
TEAE leading to death, n (%) 92 (2.0) 93 (2.0) 0.927
TEAE leading to discontinuation, n (%) 167 (3.6) 168 (3.6) 0.937
Local injection-site reaction, n (%) 177 (3.8) 106 (2.3) <0.0001
AST >3 times ULN, n (%) 85 (1.8) 81 (1.7) 0.767
ALT >3 times ULN, n (%) 108 (2.3) 103 (2.2) 0.742
Creatine kinase >10 times ULN, n (%) 24 (0.5) 23 (0.5) 0.891
Rhabdomyolysis, n (%) 11 (0.2) 8 (0.2) 0.494
Baseline eGFR >_90 mL/min/1.73 m2 (n=3714) (n=3756)
Any TEAE, n (%) 2736 (73.7) 2835 (75.5) 0.072
Any serious TEAE, n (%) 763 (20.5) 805 (21.4) 0.346
TEAE leading to death, n (%) 41 (1.1) 64 (1.7) 0.028
TEAE leading to discontinuation, n (%) 120 (3.2) 103 (2.7) 0.215
Local injection-site reaction, n (%) 155 (4.2) 81 (2.2) <0.0001
AST >3 times ULN, n (%) 61 (1.6) 61 (1.6) 0.950
ALT >3 times ULN, n (%) 76 (2.0) 94 (2.5) 0.186
Creatine kinase >10 times ULN, n (%) 19 (0.5) 16 (0.4) 0.588
Rhabdomyolysis, n (%) 8 (0.2) 7 (0.2) 0.779
ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; TEAE, treatment-emergent adverse event; ULN, upper limit of
normal.































































































numerically lowest in patients with baseline eGFR >_90 mL/min/1.73
m2 and numerically highest in patients with baseline eGFR < 60 mL/
min/1.73 m2, but with no significant interaction across categories of
baseline eGFR. Similarly, the Cholesterol Treatment Trialists collab-
oration19 has reported a trend towards smaller reduction in the risk
of MACE per mmol/L decrease in LDL-C as eGFR declines.
Although there is no complete explanation for this finding, reasons
may include differences in the pathophysiology of atherosclerosis in
patients with CKD, manifest by enhanced inflammation and complex
lipid abnormalities such as excessive LDL-C oxidation and high-
density lipoprotein cholesterol dysfunction.1,21 Furthermore, non-
atherosclerotic comorbidities present in CKD may influence out-
comes without modification by lipid-lowering therapies.
Compared to patients with better renal function, patients with
lower eGFR were older and had a higher prevalence of cardiovascu-
lar risk factors, atherosclerosis, and heart failure, which are associated
with greater absolute risk of MACE and death. However, unlike char-
acteristics such as diabetes, polyvascular disease, or prior coronary
artery bypass surgery that were associated with both greater risk of
MACE and greater MACE reduction with alirocumab in this trial,22–24
we did not find evidence for greater absolute reduction of MACE or
death with alirocumab among patients with lower eGFR at baseline.
Alirocumab did not affect the eGFR values, suggesting that the
drug does not directly affect renal function, and corroborating find-
ings by Toth et al.14 in an analysis of 4629 hypercholesterolaemic
patients treated with alirocumab or placebo up to 104 weeks.
Likewise, the FOURIER study, which included 27 564 patients with a
median follow-up of 2.2 years, demonstrated no difference in renal
function between the evolocumab and placebo groups.15 Moreover,
eGFR did not appear to influence the safety and tolerability of aliro-
cumab. In each category of baseline eGFR, the only adverse event
with greater incidence in the alirocumab group was local injection-
site reactions.
Limitations
Estimated glomerular filtration rate <30 mL/min/1.73 m2 was an ex-
clusion criterion, as is common in cardiovascular outcomes trials.
Thus, the potential benefits and risks of alirocumab treatment in
patients with severe CKD, or in those receiving dialysis treatment,
were not determined. The proportion of patients with eGFR
<60 mL/min/1.73 m2 was relatively modest (11.2%; n = 2122), limiting
power to detect an effect of alirocumab on MACE in this population.
In contrast, there were many patients with eGFR between 60 and
<90 mL/min/1.73 m2 (Stage 2 CKD). Previous analyses25 as well as
the present data indicate that these patients have an elevated risk of
MACE and death compared to those with preserved renal function,
and thus comprise an important group to assess the efficacy of
PCSK9 inhibition. Finally, the effect of alirocumab on eGFR must be
interpreted with caution given a relatively short follow-up, limiting
the ability to detect a potential influence on CKD progression.
Conclusions
In patients with recent ACS, alirocumab treatment was associated
with a reduction in MACE and fewer deaths, independent of baseline
eGFR, across a broad range above 30 mL/min/1.73 m2. This reduction
did not achieve statistical significance in the subgroup of patients with
eGFR <60 mL/min/1.73 m2. Other than local injection-site reactions,
no differences in the rates of adverse events were apparent between
treatment groups across the range of eGFR values studied.
Supplementary material
Supplementary material is available at European Heart Journal online.
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